- Home
- UGRO vs PCSA Comparison
UGRO vs PCSA Comparison
Compare UGRO & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- PCSA
- Stock Information
- Founded
- UGRO 2014
- PCSA 2011
- Country
- UGRO United States
- PCSA United States
- Employees
- UGRO N/A
- PCSA N/A
- Industry
- UGRO Industrial Specialties
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- PCSA Health Care
- Exchange
- UGRO Nasdaq
- PCSA Nasdaq
- Market Cap
- UGRO 3.8M
- PCSA 3.3M
- IPO Year
- UGRO N/A
- PCSA N/A
- Fundamental
- Price
- UGRO $0.40
- PCSA $0.21
- Analyst Decision
- UGRO Strong Buy
- PCSA Strong Buy
- Analyst Count
- UGRO 1
- PCSA 1
- Target Price
- UGRO $3.00
- PCSA $2.00
- AVG Volume (30 Days)
- UGRO 488.3K
- PCSA 7.6M
- Earning Date
- UGRO 08-12-2025
- PCSA 08-12-2025
- Dividend Yield
- UGRO N/A
- PCSA N/A
- EPS Growth
- UGRO N/A
- PCSA N/A
- EPS
- UGRO N/A
- PCSA N/A
- Revenue
- UGRO $59,985,138.00
- PCSA N/A
- Revenue This Year
- UGRO N/A
- PCSA N/A
- Revenue Next Year
- UGRO $31.25
- PCSA N/A
- P/E Ratio
- UGRO N/A
- PCSA N/A
- Revenue Growth
- UGRO N/A
- PCSA N/A
- 52 Week Low
- UGRO $0.26
- PCSA $0.15
- 52 Week High
- UGRO $1.92
- PCSA $2.27
- Technical
- Relative Strength Index (RSI)
- UGRO 50.89
- PCSA 44.08
- Support Level
- UGRO $0.42
- PCSA $0.21
- Resistance Level
- UGRO $0.55
- PCSA $0.26
- Average True Range (ATR)
- UGRO 0.07
- PCSA 0.02
- MACD
- UGRO 0.00
- PCSA 0.00
- Stochastic Oscillator
- UGRO 37.73
- PCSA 16.67
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).